Market Overview

UPDATE: Piper Jaffray Downgrades XenoPort to Neutral on Drug Commercialization Delays

Related XNPT
XenoPort Reports HORIZANT Included in New Expert Recommendations on Prevention, Treatment of RLS Augmentation
Who's The Next Big Pharma Acquisition?

Piper Jaffray reduced its rating on XenoPort (NASDAQ: XNPT) from Overweight to Neutral with a reiterated $12 price target.

Piper Jaffray said, "Given the long road ahead for '829, our cautious view on the prospects for a partnership for '829 or outright sale of the company in the near-term and the lack of visibility on cash generation (i.e., continued lackluster prescription trends for Horizant and niche-like potential for arbaclofen placarbil for spasticity), we believe upside for XNPT shares is limited in the context of an enterprise value of $430M."

XenoPort closed at $11.91 on Thursday.

Latest Ratings for XNPT

Jan 2015JefferiesMaintainsBuy
Apr 2014JefferiesInitiates Coverage onBuy
Jun 2013Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for XNPT
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (XNPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters